Dr Ellis Paintsil is a microbiologist, biostatistician, and translational researcher whose work sits at the intersection of antimicrobial resistance (AMR), microbiome science, liver disease, and global health.

His research investigates how antimicrobial resistance emerges, evolves, and influences clinical outcomes in vulnerable patient populations, particularly individuals with cirrhosis and advanced liver disease. By integrating metagenomics, resistome profiling, clinical epidemiology, and advanced statistical modelling, he develops data-driven approaches to improve infection prevention, antimicrobial stewardship, and patient outcomes. His work seeks to better understand the interactions between the gut microbiome, antimicrobial resistance, and liver disease, with the long-term goal of advancing precision approaches to infection management in patients with cirrhosis.

Alongside this translational research, Dr Paintsil conducts studies examining the global burden, trends, and future projections of liver disease, particularly in sub-Saharan Africa. Using Global Burden of Disease Study data and other international datasets, he investigates health inequalities, risk factor attribution, disease forecasting, and the potential impact of public health interventions on liver-related outcomes.

His broader research interests include One Health approaches to AMR, microbial genomics, infectious disease epidemiology, and the application of advanced analytical methods to address major global health challenges. He collaborates across clinical, microbiological, and public health disciplines and is committed to translating research into evidence that improves patient care, informs policy, and advances health equity globally.